Literature DB >> 28671151

A profile of adverse effects of antihypertensive medicines in a tertiary care clinic in Nigeria.

Abimbola O Olowofela1, Ambrose O Isah1.   

Abstract

BACKGROUND: There has been a dearth of comprehensive data on the profile of adverse reactions to antihypertensive medicines in the Nigerian setting despite increased use.
OBJECTIVE: This study was aimed to characterize the adverse reactions experienced in the homogenously black African population.
METHODS: The study was carried out at the University of Benin Teaching Hospital, Benin City, Nigeria, in consenting eligible hypertensive patients ≥18 years. Adverse reactions were sought using patient's self-report and a medicine-induced symptom checklist.
RESULTS: A total of 514 patients (340 females) aged 22-97 years were studied. Thirteen percent, 27.6%, 26.7%, 22.0%, and 10.7% were on 1, 2, 3, 4, and ≥5 medicines, respectively, for control of their blood pressure with the frequency of adverse effects increasing proportionately up to four medicines. Adverse reactions to antihypertensive medicines were reported by a total of 93 (18.1%) patients. Diuretics - 27.9%, calcium channel blockers (CCBs) - 26.8%, and angiotensin-converting enzyme inhibitors (ACEIs) - 26.8% accounted for most of the adverse reactions seen, notably frequent micturition and headaches (CCB); excessive micturition and dizziness (diuretics); dry irritating cough (ACEI). Notable complaints for all patients using the checklist were increased frequency of micturition, reduction in libido, and headaches. The reactions resulted in the discontinuation and substitution of therapy in 49.5% of the patients.
CONCLUSIONS: The characterization of these reactions in Nigerians requires further studies as frequent micturition reported is still a neglected complaint in antihypertensive therapy.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28671151      PMCID: PMC5579894          DOI: 10.4103/aam.aam_6_17

Source DB:  PubMed          Journal:  Ann Afr Med        ISSN: 0975-5764


INTRODUCTION

Hypertension is a global disease considered as the leading risk factor for cardiovascular diseases with significant health burden and accounts for 9.4 million deaths as well as 7.0% disability-adjusted life years (DALYs) of global DALYs in 2010.[1] The prevalence in Nigeria is estimated at over 28.9%.[2] It is associated with a high morbidity and mortality, from increased risks of stroke, ischemic heart disease, renal failure, congestive heart failure as well hypertensive heart diseases and the observation that it is worse in people of black ancestry.[1345] The use of medicines and other forms of nonpharmacological therapy in treating hypertension has been shown to reduce this morbidity and mortality.[67] There has been a considerable increase in the arsenal of antihypertensive medicines in the past few decades, and their use may be associated with the development of adverse reactions which is likely to result in nonadherence to therapy, increased morbidity and mortality as well as economic consequences.[89] It has also led to the withdrawal of some of these medicines from use.[10] Adverse reactions in outpatient care have been estimated to occur in about 25% of patients[11] and factors that have been associated with increased frequency of adverse reactions include, number of medicines taken by the patient's genetic disposition, age, pregnancy, and exogenous factors such as food and interactions with other medicines.[12] Identification of adverse reactions using different methods has also been advocated to limit the poor prognosis that is associated with adverse reactions.[11] The profile of adverse reactions to antihypertensive medicines in our environment has not been properly characterized given the antihypertensive armamentarium in use in this setting. There is a need to properly characterize the tolerability profile of these medicines in this environment.

METHODS

This cross-sectional study was carried out at the consultant medical outpatient department (COPD) of a tertiary hospital in Southern Nigeria. The teaching hospital is a 730-bed tertiary center, which also serves as a referral center to the neighboring states of Ondo, Anambra, Bayelsa, and Delta states. The COPD houses the hypertension clinic as well as other medical subspecialties. The study was carried out over 9 months and patients with a diagnosis of hypertension on therapy who attended the medical outpatient clinic. Hypertensive patients on antihypertensive medicines who were aged 18 years and above and consented to the study were included in the study. For this cross-sectional study, the sample size calculation was based on a previous study by Isah et al.[13] on the assessment of patient's knowledge and experience of hypertension and it revealed that about 24.8% reported that an adverse event affected their compliance. Using this figure as an estimate of the desired proportion of an adverse drug reaction (ADR), at a confidence interval of 95%, the formula for simple proportions was used.[14] A sample of 289 hypertensive patients was the minimum sample size calculated for this study. Furthermore, anticipating a 70% response to the questionnaire a sample size of 376 was estimated. However, 514 patients consented and were recruited into the study. The patients were classified as being hypertensive (defined according to the Nigerian Hypertension Society guidelines that were based on the 1999 WHO/International Society of Hypertension recommendations), as blood pressure ≥140/90 mmHg.[15] All patients who fulfilled the inclusion criteria and consented to the study were included. During the visit, their demographic characteristics, duration of hypertension as well as comorbidities were recorded in an interviewer-administered questionnaire. Antihypertensive medicines, other prescribed medications and indication for their use were noted, use of other nonprescribed medicines and herbal medicines were also recorded. ADRs to antihypertensive medicines prescribed at the last clinic visit were sought. Following the self-reported sessions, a modified checklist of antihypertensive medicines – induced symptoms as described by Bulpitt and Dollery[16] and modified based on previous studies[1317] was administered to the patients to determine what symptoms they experienced that was related to medicine use. Reported adverse reactions were also documented and classified using the Medical Dictionary for Regulatory Activities (MedDRA) system organ classification,[18] and the probability of the event being an ADR was assessed with the WHO and Naranjo causality algorithms.[1920] The outcome of the reaction was noted as well as the action patient took following the ADR.

Ethical considerations

Ethical approval was obtained from the Ethics and Research Committee of the University of Benin Teaching Hospital, and informed consent was obtained from each patient verbally. The quality of the data and its confidentiality were ensured by keeping the patients’ identity coded with their initials only. The data were fully anonymized and aggregated. Any information about any patient was kept strictly confidential and not shared with unauthorized individuals. The patient's right to confidentiality, information and privacy were respected.

Statistical analysis

Antihypertensive medications were classified into different classes: (angiotensin converting enzyme inhibitors [ACEI], beta-blockers, calcium channel blockers [CCBs], diuretics, centrally acting agents, and angiotensin receptor blockers [ARBs]). Data were analyzed using SPSS (Statistical package for the Social Sciences, SPSS Inc., Chicago, IL, USA) software version 16 for windows. Descriptive and inferential analyses were conducted as appropriate, and level of significance was set at P < 0.005.

RESULTS

A total of 514 patients were recruited into the cross-sectional descriptive study. The male:female ratio was 1:2, and the age ranged from 22 to 97 years with a mean ± (standard deviation [SD]) age of 57.91 ± 12.0 years, there was no statistically significant difference between the mean ages of the men 58.8 (12.4) and women 57.5 (11.8) studied (t-test = 0.213; P = 0.552). A total of 146 patients (28.4%) were aged 65 years and above. Regarding the educational status of the population, 172 (33.5%) had tertiary education representing the largest group. The mean (SD) duration of diagnosis of hypertension in the 514 patients was 7.8 (7.9) years, (range: 1 month–40 years) while they had been receiving treatment for a mean (SD) duration of 7.4 (7.8) years (range: 2 weeks–36 years). Only 16 (3.1%) patients were currently smoking and 67 (13%) admitted to social use of alcohol. Fifty percent (254) of the patients had comorbidities, with 85% having one comorbidity only and 14.2%, 0.8% having two and three, respectively. The different comorbidities as documented in the case records were mainly diabetes mellitus 131 (25.5%), osteoarthritis 78 (15.2%), obesity 16 (3.1%), and peptic ulcer disease 15 (2.9%) among others.

Antihypertensive medicines prescribed

A total of 67 (13%) patients were on one antihypertensive medicine (monotherapy), of which 11/67 (16.4%) of them had only antihypertensive medicine prescribed, whereas the other 56/67 (83.6%) had other medicines besides antihypertensive medicines. Four hundred and forty-seven (87%) were on combination therapy of two or more antihypertensive medicines, (combination therapy). In the patients on combination therapy, 142 (27.63%), 137 (26.63%), 113 (21.98%), and 55 (10.70%) of them had 2, 3, 4, and 5 or more antihypertensive medicines prescribed. CCBs were the most prescribed class of antihypertensive medicines 362 (70.4%) and alpha-blockers the least prescribed group 9 (1.8%). Beta-blockers 118 (23.0%) and alpha-blockers - 9 (1.8%) were prescribed only in combination therapy. The most common combinations of antihypertensive medicines were diuretics and CCBs. In patients using only one antihypertensive medicine, more patients were on ACEI 31 (46.3%), and this was closely followed by CCB at 26 (38.8%), other medicines used include ARB 5 (7.5%), centrally acting medicine 3 (4.5%), and diuretics 2 (3.0%).

Adverse drug reactions experienced

Ninety-three (18.1%) patients experienced an ADR to their antihypertensive medicines. Using the causality assessment scales to classify the probability of the adverse reactions, with WHO assessment[19] 29 (31.2%), had their adverse reactions classified as probable and 56 (60.2%) as possible. However, 7 (7.5%) and 1 (1.1%) patient(s) had experienced adverse reactions judged as being unlikely and conditional, respectively. Using the Naranjo assessment algorithm[20] to assess the adverse reactions, 55 (59.1%) were classified as having had a possible adverse reaction, 37 (39.8%) were probable, and 1 (1.1%) was doubtful. ADRs increased with increase in the number of antihypertensive medicines, and it was statistically significant [Table 1].
Table 1

Distribution of the number of antihypertensive medicines used by the 514 patients and frequency of adverse reactions experienced

Antihypertensive medicineNumber of patientsADR experienced, n (%)
16710 (14.9)
214218 (12.7)
313721 (15.3)
411332 (28.3)
≥55512 (21.8)

χ2=12.460, df=4, P=0.014 (significant). ADR=Adverse drug reaction

Distribution of the number of antihypertensive medicines used by the 514 patients and frequency of adverse reactions experienced χ2=12.460, df=4, P=0.014 (significant). ADR=Adverse drug reaction Proportionately, more men 35/174 (20.1%) than women 58/340 (17.1%) reported an adverse reactions to their antihypertensive medications, but it was not statistically significant (χ2 = 0.725, df = 1, P = 0.39). Elderly patients 20/146 (13.7%) reported fewer ADR compared to younger patients 73/368 (19.8%), although it was not significant. (χ2 = 2.658. df = 1. P = 0.103).

Profile of adverse reactions reported

Dry cough was present in 15/24 (62.5%) of those who had an adverse reaction to ACEI, and a patient had passage of loose stools, excessive micturition was seen in 19/26 (73.1%) of the patients on diuretics, while 11/25 (44%) of the patients on CCB (either as monotherapy or in combination) complained of increased frequency of micturition to their medicines distinct from an increase in volume (polyuria) seen with diuretics. The reactions are also documented in Table 2. The system organ classification is shown in Table 3, renal and urinary disorders being the most commonly reported system. Following the development of adverse reactions in these 93 patients, 46 of them (49.5%) discontinued their medicines with five of them substituting with another brand while 30 (32.2%) reduced their doses; however, 17 (18.3%) took no action [Table 2].
Table 2

Adverse reactions experienced by patients to antihypertensive medicines and actions taken by the patients following the reactions

Frequency of medicine classAdverse reactions experienced (n)Frequency (%)Action was taken by patients
Calcium channel blockers (n=362)Frequent micturition - 11, dizziness - 5, headaches - 5, others - 1025/362 (6.9)Dc - 10, reduced dose - 11, none - 4
Angiotensin converting enzyme inhibitors n=278Dry cough - 15, dizziness - 2, diarrhoea, abdominal pain - 2, others - 524/278 (8.6)Dc - 14, reduced dose - 6, none - 4
Diuretics (n=273)Excessive micturition - 19, dizziness - 5, headaches - 3, others - weakness, insomnia26/273 (9.5)Dc - 14, reduced dose - 9, none - 4
Beta blockers (n=118)Dizziness - 1, dry lips - 1, cramps in foot - 1, abnormal sensation in head - 14/118 (3.4)Dc - 1, none - 3
Centrally acting (n=95)Dizziness - 4, headaches - 3, weakness - 5, others - 512/95 (12.6)Dc - 7, reduced dose - 2, none - 2
Alpha blockers (n=9)Dizziness - 1, dryness of legs - 12/9 (22.2)Reduced dose - 2

Dc=Discontinuations

Table 3

The system organ classifications (Medical Dictionary for Regulatory Activities) of the reported adverse reactions by the hypertensive patients

System organ classification (MedDRA)Frequency (n)
Renal and urinary disorders32
Respiratory, thoracic and mediastinal disorders16
Nervous system disorders17
General disorders and administration site conditions12
Cardiac disorders12
Gastrointestinal disorders5
Reproductive system and breast disorders5
Musculoskeletal and connective tissue disorders2
Skin and subcutaneous disorders2
Eye disorders1
Psychiatric disorders1

MedDRA=Medical Dictionary for Regulatory Activities

Adverse reactions experienced by patients to antihypertensive medicines and actions taken by the patients following the reactions Dc=Discontinuations The system organ classifications (Medical Dictionary for Regulatory Activities) of the reported adverse reactions by the hypertensive patients MedDRA=Medical Dictionary for Regulatory Activities

Adverse reactions: Symptoms checklist

With the administration of a modified symptom checklist to determine drug-related symptomatology in all the patients, 405 (78.8%) had adverse reactions related to the use of their medications. The frequency of micturition, poor erection, headaches, and reduced sexual urge were the symptoms most related to drug use with 37.7%, 25.7%, 22.6%, and 21.2%, respectively. The frequencies of the other symptoms are elucidated in Table 4.
Table 4

Frequency of symptoms attributed to medicine use in the 514 hypertensive patients using the modified symptoms checklist

Symptomn (%)
Frequency of micturition190 (37.0)
Poor erection65 (25.7)
Headache116 (22.6)
Reduced sexual urge109 (21.2)
Insomnia95 (18.5)
Weakness95 (18.5)
Nightmares (bad dreams)82 (16.0)
Coughing79 (15.4)
Fatigue/little initiative74 (14.4)
Swollen ankles/oedema71 (13.8)
Muscular cramp/myalgia70 (13.6)
Dizziness upon standing up65 (12.6)
Palpitation60 (11.7)
Warm feeling/flushes in the face55 (10.7)
Dryness of mouth45 (8.8)
Impotence13 (7.3)
Other dizziness (unrelated to posture)35 (6.8)
Disturbance of taste25 (4.9)
Constipation20 (3.9)
Depressed20 (3.9)
Rash/itching19 (3.7)
Nausea19 (3.7)
Dyspnoea17 (3.3)
Cold hands/feet15 (2.9)
Urinary incontinence11 (2.1)
Nervous/restless9 (1.8)
Diarrhoea6 (1.2)
Frequency of symptoms attributed to medicine use in the 514 hypertensive patients using the modified symptoms checklist Serious adverse reactions: Notable in this outpatient-based study was the absence of serious adverse reactions as there were no deaths, hospitalizations, disabilities, or life-threatening events that required intervention to prevent permanent damage.

DISCUSSION

There is a need to define the present profile of antihypertensive medicines by finding out the present pattern of ADR which may be peculiar to our environment. The study showed that a high proportion of patients have adverse reactions to their antihypertensive medications and the higher the number of medicines used the more the adverse reactions seen, as observed in a study by Lip and Beevers.[21] Adverse reactions to medicines are an important consideration in the management of patients with hypertension as 50% of the patients who developed an adverse reaction discontinued their medicines. This finding was also seen in other studies on why patients discontinue their therapy.[1322] In assessing the causality of the ADR, most of the reactions were adjudged to be ADRs. However, a few patients had ADRs that were adjudged to be unlikely and conditional using the WHO causality assessment algorithm. Although the algorithms improved the ability to characterize the relationship between suspected medicines and the ADR, patients and health-care providers are encouraged to report all cases of adverse reactions even when they are uncertain about the probability as this expands the database of ADRs.[23] The frequency of ADRs appeared to be higher in males, although was not statistically significant. It has been suggested that the female sex may be a risk factor for the development of ADRs due to possible pharmacokinetic differences.[24] The use of the medicine induced symptom checklist was to improve the reporting of patients who may have symptoms associated with the use of their medicines and cannot recall on questioning. Different studies have used this method though modified in this study; it also showed that a high proportion of patients had symptoms that they attributed to their medicines.[161725] The frequency of erectile dysfunction reported was more following the use of the symptom checklist. Many patients attribute sexual dysfunction to their antihypertensive medicines,[2627] therefore adherence to these medicines may be poor due to their perceived adverse effect. Assessing the frequency of this complaint using a checklist or questionnaire has been shown to be helpful.[2627] It may have also contributed albeit indirectly to more males reporting adverse reactions on direct questioning. The proportion of patients who had ACEI induced cough in this study was higher than shown in other studies.[2829] The patients who used diuretics complained of excessive micturition; this had a serious impact on the patient's therapy as diuretics accounted for the highest number of reactions reported. The excessive micturition seen with diuretics may be due to the dose of diuretics, especially hydrochlorothiazide available in this environment. A study carried out in the North Central part of Nigeria also showed diuretics accounting for the highest rate of discontinuations to therapy.[30] Of interest were the reports of increased frequency of micturition following the use of CCBs. As distinct from the excessive micturition with diuretics, the CCB account for increased frequency (number of times) not reflected in the volumes of urine passed. This was observed early following the introduction of the CCBs.[3132] This finding need to be further investigated as it was also seen using the MedDRA[18] system organ classification that the renal and urinary disorders had the highest frequency. We equally note the development of dizziness and dryness of legs to alpha blockers, (though infrequently used in this study) two of the users (22%) had adverse reactions, the reactions observed may be related to the orthostatic hypotensive effect of alpha blockers.[33] Noticeable in this study, was the absence of reports of ADR to the ARBs. A reduced frequency has also been seen in another review,[9] and ARBs have also been shown to have a good tolerability profile.[34]

CONCLUSIONS

In all, there is a relatively high prevalence of adverse reactions experienced by patients on antihypertensive therapy resulting in a high rate of discontinuations as seen in this study. Notable reactions experienced by the patients include dry cough to ACEIs, excessive micturition to diuretics, and frequent micturition in patients on CCBs. Utilization of a medicine induced symptom checklist revealed symptoms which were not reported on direct questioning such as reduced libido and erectile dysfunction. Some knowledge of the profile of antihypertensive medicines in use by the physicians will aid the management of hypertension. Further studies are required to characterize this problem.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.
  26 in total

1.  Adverse drug reactions in current antihypertensive therapy: a general practice survey of 2586 patients in Norway.

Authors:  H Olsen; T Klemetsrud; H P Stokke; S Tretli; A Westheim
Journal:  Blood Press       Date:  1999       Impact factor: 2.835

2.  Discontinuation of antihypertensive drugs due to adverse events: a systematic review and meta-analysis.

Authors:  S D Ross; K S Akhras; S Zhang; M Rozinsky; L Nalysnyk
Journal:  Pharmacotherapy       Date:  2001-08       Impact factor: 4.705

3.  Adverse drug reactions--no farewell to harms.

Authors:  Jeffrey K Aronson
Journal:  Br J Clin Pharmacol       Date:  2007-02       Impact factor: 4.335

4.  Sex differences in cardiovascular drug-induced adverse reactions causing hospital admissions.

Authors:  Eline M Rodenburg; Bruno H Stricker; Loes E Visser
Journal:  Br J Clin Pharmacol       Date:  2012-12       Impact factor: 4.335

5.  Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

Authors: 
Journal:  JAMA       Date:  2002-12-18       Impact factor: 56.272

6.  A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010.

Authors:  Stephen S Lim; Theo Vos; Abraham D Flaxman; Goodarz Danaei; Kenji Shibuya; Heather Adair-Rohani; Markus Amann; H Ross Anderson; Kathryn G Andrews; Martin Aryee; Charles Atkinson; Loraine J Bacchus; Adil N Bahalim; Kalpana Balakrishnan; John Balmes; Suzanne Barker-Collo; Amanda Baxter; Michelle L Bell; Jed D Blore; Fiona Blyth; Carissa Bonner; Guilherme Borges; Rupert Bourne; Michel Boussinesq; Michael Brauer; Peter Brooks; Nigel G Bruce; Bert Brunekreef; Claire Bryan-Hancock; Chiara Bucello; Rachelle Buchbinder; Fiona Bull; Richard T Burnett; Tim E Byers; Bianca Calabria; Jonathan Carapetis; Emily Carnahan; Zoe Chafe; Fiona Charlson; Honglei Chen; Jian Shen Chen; Andrew Tai-Ann Cheng; Jennifer Christine Child; Aaron Cohen; K Ellicott Colson; Benjamin C Cowie; Sarah Darby; Susan Darling; Adrian Davis; Louisa Degenhardt; Frank Dentener; Don C Des Jarlais; Karen Devries; Mukesh Dherani; Eric L Ding; E Ray Dorsey; Tim Driscoll; Karen Edmond; Suad Eltahir Ali; Rebecca E Engell; Patricia J Erwin; Saman Fahimi; Gail Falder; Farshad Farzadfar; Alize Ferrari; Mariel M Finucane; Seth Flaxman; Francis Gerry R Fowkes; Greg Freedman; Michael K Freeman; Emmanuela Gakidou; Santu Ghosh; Edward Giovannucci; Gerhard Gmel; Kathryn Graham; Rebecca Grainger; Bridget Grant; David Gunnell; Hialy R Gutierrez; Wayne Hall; Hans W Hoek; Anthony Hogan; H Dean Hosgood; Damian Hoy; Howard Hu; Bryan J Hubbell; Sally J Hutchings; Sydney E Ibeanusi; Gemma L Jacklyn; Rashmi Jasrasaria; Jost B Jonas; Haidong Kan; John A Kanis; Nicholas Kassebaum; Norito Kawakami; Young-Ho Khang; Shahab Khatibzadeh; Jon-Paul Khoo; Cindy Kok; Francine Laden; Ratilal Lalloo; Qing Lan; Tim Lathlean; Janet L Leasher; James Leigh; Yang Li; John Kent Lin; Steven E Lipshultz; Stephanie London; Rafael Lozano; Yuan Lu; Joelle Mak; Reza Malekzadeh; Leslie Mallinger; Wagner Marcenes; Lyn March; Robin Marks; Randall Martin; Paul McGale; John McGrath; Sumi Mehta; George A Mensah; Tony R Merriman; Renata Micha; Catherine Michaud; Vinod Mishra; Khayriyyah Mohd Hanafiah; Ali A Mokdad; Lidia Morawska; Dariush Mozaffarian; Tasha Murphy; Mohsen Naghavi; Bruce Neal; Paul K Nelson; Joan Miquel Nolla; Rosana Norman; Casey Olives; Saad B Omer; Jessica Orchard; Richard Osborne; Bart Ostro; Andrew Page; Kiran D Pandey; Charles D H Parry; Erin Passmore; Jayadeep Patra; Neil Pearce; Pamela M Pelizzari; Max Petzold; Michael R Phillips; Dan Pope; C Arden Pope; John Powles; Mayuree Rao; Homie Razavi; Eva A Rehfuess; Jürgen T Rehm; Beate Ritz; Frederick P Rivara; Thomas Roberts; Carolyn Robinson; Jose A Rodriguez-Portales; Isabelle Romieu; Robin Room; Lisa C Rosenfeld; Ananya Roy; Lesley Rushton; Joshua A Salomon; Uchechukwu Sampson; Lidia Sanchez-Riera; Ella Sanman; Amir Sapkota; Soraya Seedat; Peilin Shi; Kevin Shield; Rupak Shivakoti; Gitanjali M Singh; David A Sleet; Emma Smith; Kirk R Smith; Nicolas J C Stapelberg; Kyle Steenland; Heidi Stöckl; Lars Jacob Stovner; Kurt Straif; Lahn Straney; George D Thurston; Jimmy H Tran; Rita Van Dingenen; Aaron van Donkelaar; J Lennert Veerman; Lakshmi Vijayakumar; Robert Weintraub; Myrna M Weissman; Richard A White; Harvey Whiteford; Steven T Wiersma; James D Wilkinson; Hywel C Williams; Warwick Williams; Nicholas Wilson; Anthony D Woolf; Paul Yip; Jan M Zielinski; Alan D Lopez; Christopher J L Murray; Majid Ezzati; Mohammad A AlMazroa; Ziad A Memish
Journal:  Lancet       Date:  2012-12-15       Impact factor: 79.321

7.  Secular trends in long-term sustained hypertension, long-term treatment, and cardiovascular mortality. The Framingham Heart Study 1950 to 1990.

Authors:  P A Sytkowski; R B D'Agostino; A J Belanger; W B Kannel
Journal:  Circulation       Date:  1996-02-15       Impact factor: 29.690

8.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  Hypertension       Date:  2003-12-01       Impact factor: 10.190

9.  Factors affecting the reporting of symptoms by hypertensive patients.

Authors:  M J Vandenburg; S J Evans; B J Kelly; F Bradshaw; W J Currie; W D Cooper
Journal:  Br J Clin Pharmacol       Date:  1984       Impact factor: 4.335

10.  Side effects of hypotensive agents evaluated by a self-administered questionnaire.

Authors:  C J Bulpitt; C T Dollery
Journal:  Br Med J       Date:  1973-09-01
View more
  5 in total

1.  Assessment of the state of pharmacovigilance in the South-South zone of Nigeria using WHO pharmacovigilance indicators.

Authors:  Abimbola O Opadeyi; Annie Fourrier-Réglat; Ambrose O Isah
Journal:  BMC Pharmacol Toxicol       Date:  2018-05-31       Impact factor: 2.483

2.  [Prevalence and adverse effects of antihypertensive agents in patients followed up on an ambulatory basis at the University Hospital Yalgado Ouédraogo].

Authors:  Georges Rosario Christian Millogo; Ragomzingba Frank Edgard Zongo; Anita Benao; Estelle Noëla Hoho Youl; Blaise Alexandre Bazona Bassoleth; Moussa Ouédraogo; Patrice Zabsonré; Innocent Pierre Guissou
Journal:  Pan Afr Med J       Date:  2018-01-29

3.  Assessment of drug related problems among type 2 diabetes mellitus patients with hypertension in Hiwot Fana Specialized University Hospital, Harar, Eastern Ethiopia.

Authors:  Yohanes Ayele; Kibkab Melaku; Mesay Dechasa; Mohammed Biset Ayalew; Boressa Adugna Horsa
Journal:  BMC Res Notes       Date:  2018-10-12

Review 4.  Pathophysiologically based antihypertensive pharmacotherapeutics rationality, efficacy and safety in Sub Saharan African Nations - A review.

Authors:  A A L Ajayi; O E Ajayi
Journal:  Int J Cardiol Cardiovasc Risk Prev       Date:  2021-10-28

5.  Frequency and predictors of compliance among patients taking antihypertensive medicines.

Authors:  Ekta Mutneja; Rakesh Yadav; Aparajit Ballav Dey; Pooja Gupta
Journal:  Indian Heart J       Date:  2020-04-13
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.